PH26291A - Oxetanones - Google Patents

Oxetanones Download PDF

Info

Publication number
PH26291A
PH26291A PH33205A PH33205A PH26291A PH 26291 A PH26291 A PH 26291A PH 33205 A PH33205 A PH 33205A PH 33205 A PH33205 A PH 33205A PH 26291 A PH26291 A PH 26291A
Authority
PH
Philippines
Prior art keywords
pyran
tetrahydro
hexyl
hydroxy
formyl
Prior art date
Application number
PH33205A
Other languages
English (en)
Inventor
Pierre Dr Barbier
Fernand Dr Schneider
Ulrich Widmer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PH26291A publication Critical patent/PH26291A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/10—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having one or more double bonds between ring members or between ring members and non-ring members
    • C07D305/12—Beta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PH33205A 1984-12-21 1985-12-18 Oxetanones PH26291A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH610284 1984-12-21
CH393485 1985-09-12

Publications (1)

Publication Number Publication Date
PH26291A true PH26291A (en) 1992-04-10

Family

ID=25694219

Family Applications (1)

Application Number Title Priority Date Filing Date
PH33205A PH26291A (en) 1984-12-21 1985-12-18 Oxetanones

Country Status (20)

Country Link
US (2) US4931463A (fr)
EP (1) EP0185359B1 (fr)
CN (1) CN1012643B (fr)
AT (1) ATE70061T1 (fr)
AU (1) AU583569B2 (fr)
CA (1) CA1270837A (fr)
CS (1) CS262425B2 (fr)
DE (1) DE3584829D1 (fr)
DK (1) DK166724B1 (fr)
DO (1) DOP1985004386A (fr)
FI (1) FI91403C (fr)
HU (1) HU200172B (fr)
IE (1) IE58926B1 (fr)
IL (1) IL77338A (fr)
MC (1) MC1728A1 (fr)
NO (1) NO171160C (fr)
NZ (1) NZ214565A (fr)
PH (1) PH26291A (fr)
PT (1) PT81748B (fr)
ZW (1) ZW20385A1 (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5246960A (en) * 1984-12-21 1993-09-21 Hoffmann-La Roche Inc. Oxetanones
CA1328881C (fr) * 1984-12-21 1994-04-26 Pierre Barbier Procede pour la fabrication d'oxetanones
US4895973A (en) * 1986-08-14 1990-01-23 G. D. Searle & Company Substituted glutaric acid lactones in the treatment of hyperlipidemia
US4806564A (en) * 1987-05-26 1989-02-21 Merck & Co., Inc. Antihypercholesterolemic beta-lactones
US4816477A (en) * 1987-05-26 1989-03-28 Merck & Co., Inc. Antihypercholesterolemic β-lactones
CA2035972C (fr) * 1990-02-23 2006-07-11 Martin Karpf Procede de preparation d'oxetanones
US5260310A (en) * 1990-02-26 1993-11-09 Hoffmann-La Roche Inc. Oxetanone compounds and pharmaceutical compositions containing them
CA2098167C (fr) * 1992-06-24 2006-12-19 Dorothea Isler Aliments pour humains et animaux contenant un inhibiteur de la lipase
PL191222B1 (pl) * 1997-02-05 2006-03-31 Hoffmann La Roche Zastosowanie tetrahydrolipstatyny do wytwarzania doustnego farmaceutycznego preparatu do leczenia cukrzycy typu II
SK141899A3 (en) * 1997-04-15 2000-09-12 Csir Corporate Building Pharmaceutical compositions having appetite suppressant activity
GB2396815B (en) * 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
WO2001032670A1 (fr) * 1999-10-29 2001-05-10 John Jason Gentry Mullins Dérivés d'oxétanone
EP1132389A1 (fr) 2000-03-06 2001-09-12 Vernalis Research Limited Nouveaux dérivés de l'azaindole pour le traitement de l'obésité
GB2363985B (en) * 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
ATE293477T1 (de) 2000-07-28 2005-05-15 Hoffmann La Roche Neue verwendung von lipase-inhibitoren
CA2417607C (fr) 2000-08-09 2008-01-29 Christine Feinle Utilisation d'inhibiteurs de lipase
US6900226B2 (en) 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
US6392061B1 (en) * 2000-10-16 2002-05-21 Zpro Chemical, Inc. Process for making (2S, 3S, 5S) oxetanone derivatives
WO2002044152A1 (fr) 2000-10-16 2002-06-06 F. Hoffmann-La Roche Ag Derives d'indoline et leur utilisation en tant que ligands de recepteur 5-ht2
GB0030710D0 (en) 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
BR0116605A (pt) 2000-12-27 2003-09-30 Hoffmann La Roche Composto, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, sua utilização e processo para o tratamento e profilaxia de distúrbios do sistema nervoso central, distúrbios cardiovasculares, distúrbios gastrintestinais e apnéia do sono
GB0106177D0 (en) 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
AU2002338896B2 (en) 2001-05-21 2006-04-27 F.Hoffman-La Roche Ag Quinoline derivatives as ligands for the neuropeptide Y receptor
US20030027786A1 (en) 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US6730319B2 (en) 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
US6787558B2 (en) 2001-09-28 2004-09-07 Hoffmann-La Roche Inc. Quinoline derivatives
GB0202015D0 (en) 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
PL372295A1 (en) 2002-02-04 2005-07-11 F.Hoffmann-La Roche Ag Quinoline derivatives as npy antagonists
BR0308108A (pt) 2002-02-28 2004-12-07 Hoffmann La Roche Compostos; processo para a preparação de composto; composição farmacêutica que compreende o mesmo, utilização dos compostos e método de tratamento e profilaxia de enfermidades e de obesidade
US7728153B2 (en) 2002-04-17 2010-06-01 The Burnham Institute For Medical Research Method for the asymmetric synthesis of beta-lactone compounds
WO2003088975A1 (fr) * 2002-04-17 2003-10-30 The Burnham Institute Inhibition de synthase d'acide gras par beta-lactones et par d'autres composes destines a inhiber la proliferation cellulaire
CA2489251A1 (fr) 2002-07-05 2004-01-15 F. Hoffmann-La Roche Ag Derives de quinazoline
AU2003253364B2 (en) 2002-08-07 2007-06-07 F. Hoffmann-La Roche Ag Thiazole derivatives
WO2004024726A1 (fr) 2002-09-12 2004-03-25 F. Hoffmann-La Roche Ag Composes d'acide 1h-indol-5-propionique a substitution n en tant qu'agonistes de ppar utiles dans le traitement du diabete
US6727277B1 (en) 2002-11-12 2004-04-27 Kansas State University Research Foundation Compounds affecting cholesterol absorption
DE60323130D1 (de) 2002-11-25 2008-10-02 Hoffmann La Roche Indolderivaten
GB0314967D0 (en) 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
WO2005005403A2 (fr) * 2003-07-15 2005-01-20 Ranbaxy Laboratories Limited Procede de preparation d'oxetan-2-ones
CN100393718C (zh) 2003-08-12 2008-06-11 霍夫曼-拉罗奇有限公司 作为npy拮抗剂的噻唑衍生物
CA2533463A1 (fr) 2003-08-12 2005-02-17 F. Hoffmann-La Roche Ag Antagonistes 2-amino-5-benzoylthiazole du npy
DE102004009076A1 (de) * 2004-02-23 2005-10-27 Solvay Pharmaceuticals Gmbh Alkylcarbamat-substituierte β-Lactone, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US7074822B2 (en) * 2004-02-23 2006-07-11 Solvay Pharmaceuticals Gmbh Alkyl carbamate-substituted β-lactones, process for their preparation, and pharmaceutical compositions containing them
US7121355B2 (en) * 2004-09-21 2006-10-17 Cnh America Llc Bulldozer autograding system
WO2006035296A1 (fr) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Procede de preparation d'un derive d'orlistat utile comme standard de reference dans la determination de la purete d'orlistat et procede de preparation d'orlistat
CA2609634C (fr) 2005-05-03 2011-02-01 F. Hoffmann-La Roche Ag Azapyrazinoindolines tetracycliques constituant des ligands 5-ht2
DE602006006712D1 (de) 2005-08-18 2009-06-18 Hoffmann La Roche Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
US20090171104A1 (en) * 2005-10-05 2009-07-02 Killol Patel Process for the preparation of orlistat
ATE507222T1 (de) 2005-11-30 2011-05-15 Hoffmann La Roche 1,1-dioxo-thiomorpholinyl-indolyl-methanon- derivate zur verwendung als h3-modulatoren
CA2630270A1 (fr) 2005-11-30 2007-06-07 F. Hoffmann-La Roche Ag Derives de indole-2-carboxamide substitues en 5
DE602006020482D1 (de) 2005-11-30 2011-04-14 Hoffmann La Roche 1,5-substituierte indol-2-yl amidderivative
ES2333672T3 (es) 2005-12-09 2010-02-25 F. Hoffmann-La Roche Ag Derivados de amida triciclica para tratamiento de obesidad.
CN101326187A (zh) 2005-12-15 2008-12-17 霍夫曼-拉罗奇有限公司 吡咯并[2,3-c]吡啶衍生物
BRPI0619985A2 (pt) 2005-12-16 2011-10-25 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas, métodos para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, de obesidade e de diabetes do tipo ii em um ser humano ou animal e usos dos compostos
BRPI0707916A2 (pt) * 2006-01-13 2011-05-17 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem e uso destes compostos
KR101047274B1 (ko) * 2006-01-23 2011-07-06 에프. 호프만-라 로슈 아게 H3 수용체 활성을 갖는 사이클로헥실 설폰아마이드 유도체
US7432255B2 (en) 2006-05-16 2008-10-07 Hoffmann-La Roche Inc. 1H-indol-5-yl-piperazin-1-yl-methanone derivatives
EP2032554A1 (fr) * 2006-05-30 2009-03-11 F. Hoffmann-Roche AG Dérivés de pipéridinylpyrimidine
US7514433B2 (en) 2006-08-03 2009-04-07 Hoffmann-La Roche Inc. 1H-indole-6-yl-piperazin-1-yl-methanone derivatives
US20080146559A1 (en) 2006-12-08 2008-06-19 Li Chen 4,5,6,7-Tetrahydro-Thieno [2,3-C] Pyridine Derivatives
SG182171A1 (en) * 2007-06-06 2012-07-30 Ranbaxy Lab Ltd Process for the preparation of orlistat
WO2009013195A1 (fr) 2007-07-25 2009-01-29 F. Hoffmann-La Roche Ag Dérivés d'amide d'acide benzofurane- et benzo[b]thiophène-2-carboxylique et leur utilisation comme modulateurs du récepteur h3 de l'histamine
US8258321B2 (en) * 2007-10-31 2012-09-04 Burnham Institute For Medical Research Beta-lactone compounds
US8993509B2 (en) 2009-03-31 2015-03-31 Robert Zimmerman Method for treatment of cachexia by administering inhibitors of adipose triglyceride lipase expression or activity
WO2010112569A1 (fr) 2009-03-31 2010-10-07 Robert Zimmermann Modulation de lipase de triglycérides d'adipose pour la prévention et le traitement d'une cachexie, d'une perte de poids et d'une atrophie musculaire et procédés de criblage s'y rapportant
CA2798330A1 (fr) 2010-05-05 2011-11-10 Infinity Pharmaceuticals, Inc. Tetrazolones utilises en tant qu'inhibiteurs d'acide gras synthase (fasn)
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
EP3651784B1 (fr) * 2017-07-12 2022-09-28 Mayo Foundation for Medical Education and Research Composés pour la réduction de lésions lipotoxiques
CN112079821A (zh) * 2020-09-14 2020-12-15 中山万汉制药有限公司 奥利司他与苯氨基嘧啶类化合物形成的缀合物及其制备方法与用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2478388A (en) * 1945-09-28 1949-08-09 Eastman Kodak Co beta-lactones from unsaturated aldehydes and unsaturated ketones
JPS608117B2 (ja) * 1977-02-08 1985-02-28 財団法人微生物化学研究会 新生理活性物質エステラスチンおよびその製造法
GB2023604B (en) * 1978-05-25 1982-07-28 Microbial Chem Res Found Physiologically active derivatives of esterastin and production thereof
JPS56128774A (en) * 1980-03-14 1981-10-08 Microbial Chem Res Found New physiologically active substance ebelactone and its preparation
CA1247547A (fr) * 1983-06-22 1988-12-28 Paul Hadvary Derives de leucine

Also Published As

Publication number Publication date
US5175186A (en) 1992-12-29
ZW20385A1 (en) 1986-03-05
DK600385D0 (da) 1985-12-20
CN1012643B (zh) 1991-05-22
AU583569B2 (en) 1989-05-04
HUT39440A (en) 1986-09-29
IE58926B1 (en) 1993-12-01
EP0185359A3 (en) 1987-08-26
DK166724B1 (da) 1993-07-05
US4931463A (en) 1990-06-05
DK600385A (da) 1986-06-22
HU200172B (en) 1990-04-28
CN85108888A (zh) 1986-07-09
IL77338A (en) 1991-04-15
NO171160C (no) 1993-02-03
MC1728A1 (fr) 1986-12-15
FI854797A7 (fi) 1986-06-22
EP0185359A2 (fr) 1986-06-25
IE853277L (en) 1986-06-21
NZ214565A (en) 1989-06-28
NO855213L (no) 1986-06-23
NO171160B (no) 1992-10-26
AU5125985A (en) 1986-06-26
PT81748A (en) 1986-01-02
FI854797A0 (fi) 1985-12-04
CA1270837A (fr) 1990-06-26
CS262425B2 (en) 1989-03-14
ATE70061T1 (de) 1991-12-15
FI91403B (fi) 1994-03-15
DOP1985004386A (es) 1991-04-20
DE3584829D1 (de) 1992-01-16
FI91403C (fi) 1994-06-27
PT81748B (pt) 1988-07-29
EP0185359B1 (fr) 1991-12-04

Similar Documents

Publication Publication Date Title
US4931463A (en) Oxetanones
US5246960A (en) Oxetanones
Clive et al. Total synthesis of both (+)-compactin and (+)-mevinolin. A general strategy based on the use of a special titanium reagent for dicarbonyl coupling
Rojo et al. Stereoselective synthesis of substituted γ-butyrolactones from γ-hydroxy-α, β-unsaturated phenyl sulfones
US3881017A (en) 9-Thiaprostaglandin compositions
US5990346A (en) Prostaglandins and processes for production thereof
DE2629644A1 (de) 16,16-spirocycloalkylprostaglandine und verfahren zu ihrer herstellung
US4885246A (en) Optically active carbacyclin intermediates and processes for the preparation thereof
KR950008310B1 (ko) 옥세타논의 제조방법
Domínguez et al. Flexible and stereoselective construction of polypropionate chains from enantiomerically pure γ-hydroxy-α, β-unsaturated sulfones
US4359581A (en) Process for the production of caracyclin intermediates
US4681951A (en) Bicyclo(3.3.0)octene derivatives
US5102793A (en) Stereospecific keto reduction of bicyclooctandione-carboxylic acid esters by microorganisms
USRE29469E (en) Hydroxylated 15-deoxy derivatives of 9-hydroxyl-13-trans-prostenoic acid
US5216177A (en) Method of preparing trans-3,4-disubstituted-γ-lactones
GB2270914A (en) HIV protease inhibitor compounds
US4920106A (en) Acetylenic cyclic carbonates
US4526991A (en) 2,6-Dioxa-bicyclo-[2,2,2]-octane-7-yl-acetaldehydes
US4107441A (en) Novel 16 hydroxy 15-deoxy-5-cis-prostenoic acids and esters
US4005106A (en) 3β-[(Methoxalyl)oxy]-2α-(3-oxo-1-octenyl)-5-oxo-1β-cyclopentaneheptanoic acid and process
HU192316B (en) Process for producing new carbacyclin derivatives and pharmaceutical compositions containing them
JPH03220158A (ja) 光学活性カルバサイクリン誘導体の製造方法
US3992412A (en) 2α-(2-Carboxy-2-oxoethyl)-3β-hydroxy-5-oxo-1β-cyclopentaneheptanoic acid and process
JPH0645575B2 (ja) 3―メチレン―2,6,7―三置換ビシクロ[3.3.0オクタン類
EP0084408A1 (fr) Composés du bicyclooctane, leur préparation et utilisation